XBI
$144.32-3.65%
as of close, Oct 16, 2026
☾ AH $144.32 -3.65%
SPDR S&P Biotech ETFETF · Themes
XBI holdings (2026)
All 151 positions in SPDR S&P Biotech ETF, ranked by portfolio weight — led by MRNA at 4.5%. Positions in stocks ChartRow doesn't track still appear, ranked by weight, without returns. Not investment advice.
Holdings as of Jun 30, 2026, the fund’s latest quarterly SEC report. Weights are updated to today’s prices (as of market close, Oct 16, 2026) — an estimate of today, not the filed figure; switch the table below to see them as filed.
Holdings
151
positions in the latest filing
Largest holding
4.5%
MRNA · estimated today
Top 10 weight
19%
concentration · estimated today
On ChartRow
85.3%
fund weight in tickers ChartRow tracks
Holdings as of
Jun 30, 2026
latest quarterly SEC report
Top 10 holdings#
CompanyWeight1D
7Apogee Therapeutics Inc
1.6%—
Sector weights#
SectorWeight
Healthcare
84.7%
Not on ChartRow
14.7%
Financials
0.6%
Estimated portfolio characteristics#
Median P/E
29.9
per member, trailing
P/B
5.0
weighted
Dividend yield
0.11%
weighted
Earnings growth
-98.9%
aggregate TTM, YoY
Avg market cap
$29B
weighted
Estimated by our own bottom-up analysis of the fund’s SEC-filed holdings, covering 85% of portfolio weight (26% carries a valid trailing P/E). Funds publish similar figures on their own sites; ours are recomputed daily from public data.
XBI holdings by weight#
1–100 of 151Weightsthe Jun 30, 2026 filing rolled forward on price — an estimate (as of market close, Oct 16, 2026)
| # | Company | Weight | Price | 1D | YTD total | 1Y total | Mkt cap |
|---|---|---|---|---|---|---|---|
| 1 | MRNAModerna Inc. | 4.54% | $218.00 | -7.82% | +639.27% | +703.28% | $87B |
| 2 | IOVAIovance Biotherapeutics Inc. | 1.92% | $13.64 | -7.37% | — | — | $6B |
| 3 | TWSTTwist Bioscience Corporation | 1.90% | $132.85 | -8.06% | +318.51% | +331.71% | $8B |
| 4 | NTRANatera Inc. | 1.76% | $393.54 | -2.78% | +71.74% | +117.92% | $57B |
| 5 | HALOHalozyme Therapeutics Inc. | 1.68% | $121.83 | +0.26% | +81.04% | +82.18% | $14B |
| 6 | GRALGRAIL Inc. Common Stock | 1.64% | $117.58 | -13.20% | — | — | $5B |
| 7 | Apogee Therapeutics Inc | 1.56% | — | — | — | — | — |
| 8 | PCVXVaxcyte Inc. | 1.36% | $63.61 | -2.55% | — | — | $9B |
| 9 | KYMRKymera Therapeutics Inc. | 1.30% | $104.71 | -3.17% | — | — | $9B |
| 10 | REGNRegeneron Pharmaceuticals Inc. | 1.27% | $790.95 | -0.68% | +2.84% | +39.64% | $81B |
| 11 | KODKodiak Sciences Inc | 1.25% | $85.68 | -2.77% | — | — | $5B |
| 12 | GILDGilead Sciences Inc. | 1.25% | $156.19 | -0.75% | +29.54% | +35.81% | $194B |
| 13 | AMGNAmgen Inc. | 1.24% | $432.56 | -0.34% | +34.84% | +50.26% | $234B |
| 14 | ABBVAbbVie Inc. | 1.23% | $285.38 | +0.70% | +28.65% | +29.57% | $504B |
| 15 | RVMDRevolution Medicines Inc. | 1.20% | $178.07 | -5.91% | +123.43% | +258.21% | $38B |
| 16 | PTGXProtagonist Therapeutics Inc. | 1.18% | $128.78 | -5.69% | — | — | $8B |
| 17 | BIIBBiogen Inc. | 1.16% | $232.65 | -1.15% | +32.20% | +63.54% | $34B |
| 18 | EXELExelixis Inc. | 1.15% | $62.25 | -0.92% | +41.98% | +58.71% | $15B |
| 19 | ROIVRoivant Sciences Ltd. | 1.15% | $33.52 | -1.53% | +54.52% | +95.97% | $24B |
| 20 | TGTXTG Therapeutics Inc. | 1.12% | $54.00 | -3.57% | — | — | $8B |
| 21 | IBRXImmunityBio Inc. | 1.12% | $9.20 | -8.00% | +363.64% | +262.85% | $10B |
| 22 | VRTXVertex Pharmaceuticals Incorporated | 1.11% | $499.78 | -1.76% | +10.23% | +22.30% | $127B |
| 23 | ORKAOruka Therapeutics Inc. | 1.09% | $71.98 | -2.56% | — | — | $5B |
| 24 | uniQure NV | 1.08% | — | — | — | — | — |
| 25 | SMMTSummit Therapeutics Inc. Common Stock | 1.06% | $14.65 | -4.72% | -16.35% | -33.41% | $12B |
| 26 | CGONCG Oncology Inc. | 1.06% | $59.87 | -3.23% | — | — | $5B |
| 27 | INCYIncyte Corp. | 1.03% | $113.13 | -0.12% | +14.48% | +29.50% | $23B |
| 28 | SYRESpyre Therapeutics Inc. | 1.03% | $79.95 | -0.19% | — | — | $7B |
| 29 | TVTXTravere Therapeutics Inc. | 1.03% | $49.64 | -5.97% | — | — | $5B |
| 30 | INSMInsmed Incorporated | 1.02% | $96.27 | -2.97% | -44.69% | -41.01% | $21B |
| 31 | RLAYRelay Therapeutics Inc. | 1.00% | $16.28 | -5.90% | — | — | $4B |
| 32 | KRYSKrystal Biotech Inc. | 0.98% | $316.69 | -4.03% | +28.41% | +68.10% | $9B |
| 33 | RYTMRhythm Pharmaceuticals Inc. | 0.98% | $86.20 | -2.02% | — | — | $6B |
| 34 | PRAXPraxis Precision Medicines Inc. | 0.98% | $241.78 | -2.60% | -17.98% | +48.58% | $7B |
| 35 | ERASErasca Inc. | 0.97% | $13.39 | -9.95% | — | — | $5B |
| 36 | Nuvalent Inc | 0.97% | — | — | — | — | — |
| 37 | CRSPCRISPR Therapeutics AG | 0.97% | $49.28 | -4.35% | — | — | $5B |
| 38 | BBIOBridgeBio Pharma Inc. | 0.96% | $66.38 | -1.12% | -13.20% | +20.64% | $13B |
| 39 | UTHRUnited Therapeutics Corporation | 0.95% | $533.32 | -1.51% | +9.41% | +23.21% | $23B |
| 40 | BMRNBioMarin Pharmaceutical Inc. | 0.95% | $54.68 | -2.44% | -7.99% | +3.27% | $11B |
| 41 | MDGLMadrigal Pharmaceuticals Inc. | 0.93% | $449.53 | -2.24% | -22.77% | +1.72% | $10B |
| 42 | DNTHDianthus Therapeutics Inc. | 0.92% | $72.22 | -3.10% | — | — | $4B |
| 43 | Catalyst Pharmaceuticals Inc | 0.91% | — | — | — | — | — |
| 44 | COGTCogent Biosciences Inc. | 0.91% | $29.53 | +0.07% | — | — | $5B |
| 45 | ALKSAlkermes plc | 0.91% | $41.22 | +2.79% | — | — | $7B |
| 46 | CYTKCytokinetics Incorporated | 0.90% | $61.99 | -3.02% | -2.50% | +5.07% | $8B |
| 47 | VKTXViking Therapeutics Inc. | 0.88% | $25.18 | -8.00% | — | — | $3B |
| 48 | SRRKScholar Rock Holding Corporation | 0.88% | $39.92 | -1.77% | — | — | $5B |
| 49 | SLSSELLAS Life Sciences Group Inc. | 0.84% | $9.98 | -11.99% | — | — | $2B |
| 50 | MIRMMirum Pharmaceuticals Inc. | 0.83% | $80.19 | -2.67% | — | — | $5B |
| 51 | NVAXNovavax Inc. | 0.83% | $11.25 | -12.25% | — | — | $2B |
| 52 | NBIXNeurocrine Biosciences Inc. | 0.82% | $135.77 | -0.86% | -4.32% | -1.32% | $14B |
| 53 | ARQTArcutis Biotherapeutics Inc. | 0.82% | $28.84 | -0.89% | — | — | $4B |
| 54 | ADMAADMA Biologics Inc | 0.81% | $10.69 | -0.37% | — | — | $2B |
| 55 | PTCTPTC Therapeutics Inc. | 0.78% | $59.27 | -2.82% | — | — | $5B |
| 56 | ALNYAlnylam Pharmaceuticals Inc. | 0.77% | $231.85 | -0.93% | -41.70% | -51.81% | $31B |
| 57 | BEAMBeam Therapeutics Inc. | 0.77% | $23.50 | -4.97% | — | — | $2B |
| 58 | ARWRArrowhead Pharmaceuticals Inc. | 0.77% | $55.91 | -4.43% | -15.80% | +43.44% | $8B |
| 59 | RXRXRecursion Pharmaceuticals Inc. | 0.75% | $3.47 | -16.71% | — | — | $2B |
| 60 | SRPTSarepta Therapeutics Inc. Common Stock (DE) | 0.74% | $17.11 | -3.82% | — | — | $2B |
| 61 | ACADACADIA Pharmaceuticals Inc. | 0.74% | $19.13 | -2.94% | — | — | $3B |
| 62 | IDYAIDEAYA Biosciences Inc. | 0.74% | $32.88 | -2.87% | — | — | $3B |
| 63 | VRDNViridian Therapeutics Inc. | 0.73% | $19.03 | -2.71% | — | — | $2B |
| 64 | BCRXBioCryst Pharmaceuticals Inc. | 0.73% | $7.79 | -2.93% | — | — | $2B |
| 65 | VERAVera Therapeutics Inc. | 0.72% | $27.90 | -2.35% | — | — | $2B |
| 66 | CDNACareDx Inc. | 0.71% | $64.06 | -3.92% | — | — | $3B |
| 67 | IMVTImmunovant Inc. | 0.67% | $26.76 | -2.74% | — | — | $6B |
| 68 | NTLAIntellia Therapeutics Inc. | 0.64% | $11.42 | +0.71% | — | — | $2B |
| 69 | VCYTVeracyte Inc. | 0.63% | $43.15 | -2.79% | — | — | $3B |
| 70 | CELCCelcuity Inc. | 0.62% | $56.58 | -6.17% | — | — | $3B |
| 71 | TNGXTango Therapeutics Inc. | 0.62% | $22.05 | -2.86% | — | — | $4B |
| 72 | AGIOAgios Pharmaceuticals Inc. | 0.61% | $31.36 | -2.97% | — | — | $2B |
| 73 | DNLIDenali Therapeutics Inc. | 0.60% | $17.60 | -4.03% | — | — | $3B |
| 74 | NRIXNurix Therapeutics Inc. | 0.59% | $24.40 | -2.20% | — | — | $3B |
| 75 | DYNDyne Therapeutics Inc. | 0.58% | $14.25 | -6.80% | — | — | $3B |
| 76 | IONSIonis Pharmaceuticals Inc. | 0.57% | $42.97 | -2.61% | — | — | $7B |
| 77 | PURRHyperliquid Strategies Inc | 0.56% | $9.07 | -7.45% | — | — | $2B |
| 78 | MLYSMineralys Therapeutics Inc. | 0.56% | $20.32 | -6.10% | — | — | $2B |
| 79 | RCUSArcus Biosciences Inc. | 0.56% | $22.11 | -3.11% | — | — | $3B |
| 80 | CLDXCelldex Therapeutics Inc. | 0.54% | $27.54 | -4.80% | — | — | $2B |
| 81 | IRONDisc Medicine Inc. | 0.53% | $56.94 | +0.51% | — | — | $2B |
| 82 | RAREUltragenyx Pharmaceutical Inc. | 0.52% | $14.55 | -4.09% | — | — | $1B |
| 83 | Capricor Therapeutics Inc | 0.51% | — | — | — | — | — |
| 84 | Monte Rosa Therapeutics Inc | 0.50% | — | — | — | — | — |
| 85 | IMNMImmunome Inc. | 0.48% | $16.47 | -5.34% | — | — | $2B |
| 86 | VIRVir Biotechnology Inc. | 0.48% | $9.96 | -4.87% | — | — | $2B |
| 87 | PVLAPalvella Therapeutics Inc. | 0.48% | $120.45 | -5.41% | — | — | $2B |
| 88 | VCELVericel Corporation | 0.47% | $40.15 | -2.12% | — | — | $2B |
| 89 | SNDXSyndax Pharmaceuticals Inc. | 0.44% | $12.92 | -5.38% | — | — | $1B |
| 90 | PGENPrecigen Inc. | 0.44% | $6.39 | -11.32% | — | — | $2B |
| 91 | XNCRXencor Inc. | 0.43% | $22.83 | -4.88% | — | — | $2B |
| 92 | Corvus Pharmaceuticals Inc | 0.43% | — | — | — | — | — |
| 93 | Cullinan Therapeutics Inc | 0.42% | — | — | — | — | — |
| 94 | ABSIAbsci Corporation | 0.42% | $8.25 | -7.09% | — | — | $1B |
| 95 | BHVNBiohaven Ltd. Common Shares | 0.40% | $10.80 | -5.56% | — | — | $2B |
| 96 | ORICOric Pharmaceuticals Inc. | 0.39% | $12.35 | -3.29% | — | — | $1B |
| 97 | STOKStoke Therapeutics Inc. | 0.37% | $24.20 | -1.67% | — | — | $2B |
| 98 | Ardelyx Inc | 0.37% | — | — | — | — | — |
| 99 | Avalo Therapeutics Inc | 0.37% | — | — | — | — | — |
| 100 | ANABAnaptysBio Inc. | 0.36% | $46.58 | -4.37% | — | — | $1B |
Methodology#
Holdings and weights are sourced from the fund’s portfolio as disclosed to the SEC on Form N-PORT — a public filing. Portfolio filings are quarterly (public ~60 days after quarter end), so we anchor on the latest one and roll each weight forward daily by that holding’s price move, keeping the numbers current between filings; positions in stocks ChartRow doesn’t track carry their filed weight unchanged and show “—” where we have no data. Returns are total returns (dividends reinvested). One row per company, not per ticker: when a fund holds more than one share class of the same company (Alphabet’s GOOGL and GOOG, for example), we combine them into a single row whose weight is the sum of its classes. Past performance does not predict future returns; not investment advice.
FAQ#
- What are the top 10 holdings of XBI?
- XBI's top 10 holdings are Moderna Inc. (MRNA), 4.5%; Iovance Biotherapeutics Inc. (IOVA), 1.9%; Twist Bioscience Corporation (TWST), 1.9%; Natera Inc. (NTRA), 1.8%; Halozyme Therapeutics Inc. (HALO), 1.7%; GRAIL Inc. Common Stock (GRAL), 1.6%; Apogee Therapeutics Inc, 1.6%; Vaxcyte Inc. (PCVX), 1.4%; Kymera Therapeutics Inc. (KYMR), 1.3%; Regeneron Pharmaceuticals Inc. (REGN), 1.3% — together about 19% of the fund, per its Jun 30, 2026 SEC filing with weights rolled forward to today.
- How many holdings does XBI have?
- SPDR S&P Biotech ETF (XBI) held 151 positions as of Jun 30, 2026, the date of its latest public portfolio report to the SEC.
- How current are XBI's holdings?
- The list of holdings is as of Jun 30, 2026. Funds report their full portfolio to the SEC on Form N-PORT, and the report for the last month of each fiscal quarter becomes public about 60 days after that month ends, so the newest public portfolio is always two to five months old. Between reports ChartRow updates each weight daily by that holding's price move, so the weights estimate today; the positions themselves change only when the next report is published. A fund's own website may list more recent holdings.
- Is ChartRow affiliated with XBI or State Street?
- No. ChartRow is independent and is not affiliated with, sponsored by, or endorsed by State Street or SPDR S&P Biotech ETF. Everything on this page is derived independently from the fund's public SEC filings; fund names and trademarks belong to their owners. For information only — not investment advice.